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Objective: Investigate the clinical landscape of ovarian carcinoma(OC) over time. 23 
Design: Register-based prospectively collected data. 24 
Setting: South-East Scotland 25 
Sample: 2805 OC patients diagnosed 1981-2015. 26 
Methods: Survival times were visualised using the Kaplan-Meier method; median survival, 5-27 
year survival probabilities and associated restricted mean survival time analyses were used to 28 
quantify survival differences 29 
Main Outcome Measures: Disease-specific survival.  30 
Results: Significant increase in disease-specific survival(DSS) from 1981-1985 to 2011-2015 31 
was observed (median 1.73 vs 4.23 years, p<0.0001). Corresponding increase in progression-32 
free survival(PFS) was not statistically significant (median 1.22 vs 1.58 years, p=0.2568). An 33 
increase in the proportion of cases with low residual disease volume (RD) (<2cm RD) following 34 
debulking was observed (54.0% vs 87.7%, p<0.0001). The proportion of high grade serous 35 
(HGS) cases increased (p<0.0001), while endometrioid and mucinous cases decreased 36 
(p=0.0005 and p=0.0002). Increases in stage IV HGSOC incidence (p=0.0009) and stage IV 37 
HGSOC DSS (p=0.0122) were observed. Increasing median age at diagnosis correlated with 38 
increasing Eastern Cooperative Oncology Group Performance Status (ECOG PS) over time 39 
(r=0.86). 40 
Conclusions: OC DSS has improved over the last 35 years; PFS has not significantly increased, 41 
highlighting that improvement in outcome has been limited to extending post-relapse 42 
survival. Distribution of stage at diagnosis, histological subtype and RD following debulking 43 
have changed over time, reflecting evolution in tumour classification, staging and optimal 44 
debulking definitions (from low RD to minimal or zero RD). Histology, stage, RD and ECOG PS 45 
remain reliable outcome predictors. Increasing median age at diagnosis and ECOG PS indicates 46 
demographic shifts in the clinical population. 47 
 48 
Keywords: ovarian cancer, survival, prognosis, diagnosis. 49 
Tweetable Abstract: Significant improvement in ovarian carcinoma survival has been seen 50 
over time. Most of this improvement is due to an extension of survival following disease 51 
relapse 52 
 53 





With over 290, 000 new diagnoses and 180, 000 deaths per year worldwide, ovarian cancer is 57 
the most lethal of all gynaecological malignancies1. This is attributed, in part, to the high 58 
frequency at which these malignancies are diagnosed at advanced stage, which represents a 59 
major clinical challenge. For these advanced stage cases, the 5-year survival rate remains poor 60 
at under 30%2.  61 
 62 
It is now recognised that ovarian carcinoma (OC) - which represents around 90% of ovarian 63 
cancer cases - is a collection of discrete diseases, the five main histotypes of which are high 64 
grade serous (HGS), endometrioid, clear cell (CC), mucinous and low grade serous (LGS) OC3. 65 
These histotypes display distinct clinical characteristics, with differing intrinsic 66 
chemosensitivity, typical stage at diagnosis and overall survival outcome4. Moreover, these 67 
histotypes are now known to arise from distinct gynaecological sites5-9.  68 
 69 
Despite intensive research efforts to find further therapeutic options, the standard-of-care for 70 
OC has largely remained static in recent decades, comprising maximal cytoreductive debulking 71 
surgery followed by platinum based chemotherapy, frequently in combination with taxanes10. 72 
In recent years, the use of anti-angiogenic treatments and PARP inhibitors has been integrated 73 
into routine practice, with several trials demonstrating prolonged progression-free survival 74 
largely in the relapse disease setting11-16. Recognition of the biologically distinct histotypes 75 
within OC has highlighted the need for identifying new histotype-specific therapeutic 76 
treatments17 and has led to rationally designed histotype-specific trials of biological agents18, 77 
19.  78 
 79 
It is well established that disease stage at diagnosis, patient age and ECOG performance status 80 
(ECOG PS)20-23 are associated with differential survival outcomes in OC patients; moreover, 81 
optimal surgical cytoreduction has emerged as one of the most important determinants of 82 
outcome24-26. The definition of optimal cytoreduction has evolved alongside our 83 
understanding of OC as a disease entity27-31, with the goal of surgery evolving from <2cm 84 
maximal dimension of the largest residual disease (RD) lesion to minimal RD (<0.5cm) to the 85 




Here, we investigate the changing clinical landscape of ovarian carcinoma patients from 88 
South-East Scotland (population 1.4 million) over the last 35 years (1981 – 2015) using data 89 







Cases were identified using the Edinburgh Ovarian Cancer Database; patient demographics 95 
and survival data, prospectively collected as part of routine clinical care, were retrieved from 96 
the database. No independent ethical approval for this study was required, as determined by 97 
the South East Scotland Research Ethics Service. 98 
 99 
All pathologically confirmed epithelial OC diagnoses of serous, mucinous, endometrioid or 100 
clear cell histological type between 1981-2015 were included (Figure S1), including cases 101 
recorded as primary fallopian tube or primary peritoneal carcinoma, representing the vast 102 
majority of OC cases in the region (for example, cases treated solely within private practice 103 
will not have attended at the Edinburgh Cancer Centre). All other histotypes were excluded. 104 
Historically diagnosed grade II serous carcinomas (n=189) were included with documented 105 
grade III serous carcinomas (n=1010) and HGSOCs (n=554). Well differentiated serous (n=107) 106 
OCs were included alongside contemporary diagnoses of LGSOC (n=10). Serous carcinomas 107 
with unknown grade or variable differentiation were excluded (n=96). 51.0% of cases 108 
represented either contemporary diagnoses (2010 onwards), or cases where histotype has 109 
been confirmed by contemporary pathology review by an expert gynaecological pathologist 110 




Patients were classified into 5-year cohorts using date of pathologically confirmed OC 115 
diagnosis (1981 – 1985, 1986 – 1990, 1991 – 1995, 1996 – 2000, 2001 – 2005, 2006 – 2010, 116 
2011 – 2015). Staging information was based on the International Federation of Obstetrics 117 
and Gynaecology (FIGO) staging system. Debulking status was classified as <2cm and ≥2cm 118 
residual disease (RD). Debulking status could not be resolved beyond <2cm due to the 119 
retrospective nature of these data and historic classification of <2cm RD as optimal debulking 120 
prior to 2008. ECOG performance status (PS) was categorised discretely from 0 (PS 0) – 4 (PS 121 
4). Due to the low number of cases with PS 4 (n=6), these cases were excluded from PS 122 
analysis. 5 distinct cases were excluded from survival analysis (4 from disease-specific survival 123 




Statistical analysis  126 
DSS was evaluated as time from date of diagnosis to disease-specific death. Deaths from other 127 
causes were censored. PFS was evaluated as time from date of diagnosis to date of OC 128 
progression40, where progression was established by radiologically confirmed progressive 129 
disease (PD), CA125 PD or clinical deterioration as determined by the treating physician. 130 
Statistical analyses were performed using R 3.6.1. Survival analyses were visualised using the 131 
Kaplan-Meier method. Survival statistics are presented with median survival with 132 
corresponding 95% confidence intervals (CIs), alongside 5- and 10-year survival rates and 133 
statistical comparison by restricted mean survival time analysis. Multivariable analyses were 134 
performed using Cox proportional hazards regression models, stratified by RD, histotype and 135 
age or PS. Differences in frequency were analysed using the Chi-squared test. P<0.05 was 136 




               RESULTS 139 
 140 
2805 patients met the inclusion criteria (Figure S1, Table 1). 51.0% of all cases represented 141 
contemporary diagnoses (2010 onwards) or had their histotype confirmed by pathology 142 
review: 56.5% HGS; 52.2% LGS; 42.1% endometrioid; 53.2% clear cell; 27.7% mucinous (Table 143 
S1). 144 
 145 
Outcome of OC across all time periods 146 
 147 
Across the whole OC cohort, the median DSS was 3.13 years (95% CI: 2.87 - 3.42) and the 148 
median PFS was 1.45 years (95% CI: 1.36 - 1.54). The overall 5-year and 10-year DSS rates were 149 
38.5% (95% CI: 36.6% - 40.5%) and 27.6% (95% CI: 25.8% - 29.6%). 150 
 151 
The current 5-year DSS, given by the 2011-2015 estimate, was 45.6% (95% CI: 40.7% - 51.1%). 152 
The DSS across the year ranges, inclusive of all histotypes, increased incrementally (Figure 1, 153 
Table S2), with cohorts diagnosed after 1995 demonstrating significant increases in median 154 
DSS when compared to the 1981-1985 cohort. The greatest improvement was observed in the 155 
most contemporary cohort patient group (diagnosed 2011-2015), with a significantly 156 
increased median DSS (4.23 years, 95% CI 3.73-5.13 vs 1.73 years, 95% CI: 1.53-2.21 in 1981-157 
1985, p<0.0001). Conversely, PFS across the year ranges demonstrated little improvement, 158 
with no significant difference between 1981-1985 and 2011-2015 (median PFS 1.22 years, 95% 159 
CI: 1.09-1.78 vs 1.58 years, 95% CI: 1.41-1.86, p=0.2568) (Figure 2, Table S3). While there was 160 
an apparent correlative increase in PFS with increase in DSS across time (r=0.80) (Figure S2), 161 
the magnitude of PFS increase was slight.  162 
 163 
Patterns in clinicopathological features over time 164 
 165 
Histotype 166 
An increase in the proportion of HGSOC cases was seen (129 of 223 cases, 57.8% in 1981-1985 167 
vs 373 of 544 cases, 68.6% in 2011-2015, p<0.0001 across diagnosis periods) while the 168 
proportion of mucinous cases decreased significantly (38 of 223 cases, 17.0% in 1981-1985 vs 169 
44 of 544 cases, 8.1% in 2011-2015, p=0.0002 across diagnosis periods). The proportion of 170 
endometrioid cases decreased over time (23 of 223 cases, 10.3% in 1981-1985 vs 50 of 544 171 
cases, 9.2% in 2011-2015, p=0.0005 across diagnosis periods).  172 
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Stage at Diagnosis & RD following debulking 173 
An overall increase in the proportion of Stage IV HGSOC patients was seen over the year 174 
ranges (14 of 122 cases, 11.5% in 1981-1985 vs 85 of 317 cases, 26.8% in 2011-2015, 175 
p=0.0009). A corresponding decrease in HGSOC patients presenting with Stage I was seen (14 176 
of 122 cases, 11.4% in 1981-1985 vs 16 of 317 cases, 5.0% in 2011-2015, p=0.0293). The 177 
proportion of cases with <2cm RD increased greatly in 2011-2015 to 87.7% (vs 54.0% in 1981-178 
1985, p<0.0001). 179 
 180 
ECOG Performance Status & Age at Diagnosis 181 
The proportion of PS 0 cases decreased over time (73 of 173 cases, 42.2% in 1981-1985 vs 98 182 
of 451 cases, 21.7% in 2011-2015, p<0.0001), while the proportion of PS 2 cases increased (17 183 
of 173 cases, 9.8% in 1981-1985 vs 95 of 451 cases, 21.1% in 2011-2015, p=0.0016) (table 1). 184 
The median age at diagnosis significantly increases across time (57 years in 1981-1985 vs 66 185 
years in 2011-2015, p<0.0001) (Figure 3A). When plotted against the mean PS for each 5-year 186 
cohort, a strong correlation can be observed (r=0.86) (Figure 3B), consistent of the overall 187 
correlation between age and PS across the cohort (Figure S3).  188 
 189 
Associations between histological subtype and outcome 190 
 191 
HGSOC demonstrated the lowest 5-year DSS (25.0%, 95% CI: 22.9% - 27.2%) of the histotypes 192 
(Figure 2A), while mucinous carcinomas showed the most favourable DSS (5-year survival: 193 
75.0%, 95% CI: 69.9% - 80.4%, p<0.0001 vs HGSOC), followed by LGSOC (5-year survival: 194 
63.8%, 95% CI: 55.2% - 73.8%, p<0.0001 vs HGSOC) and endometrioid OC (5-year survival: 195 
60.0%, 95% CI: 55.1% - 65.4%, p<0.0001 vs HGSOC). Stage-specific analysis revealed markedly 196 
poor outcome in mucinous and CC OC diagnoses at advanced stage (FIGO III/IV) (mucinous 197 
median DSS: 0.88 years, 95% CI: 0.55 – 1.75, CC median DSS: 0.85 years, 95% CI: 0.65 – 1.34), 198 
while LGSOC showed the highest median survival of 6.76 years in this analysis (Figure 2E). 199 
Corresponding early stage (Stage I and II) DSS analysis mirrored the results of the overall DSS 200 
analysis (Figure 2A). 201 
 202 
Associations between other clinicopathologic features and outcome 203 
 204 
Low RD volume following surgical debulking, lower PS and earlier stage were all associated 205 
with significantly prolonged DSS (Figure 2B, 2C, 2D). Patients with <2cm RD demonstrated 206 
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significantly higher median survival (7.33 yrs, 95% CI: 6.46 – 8.80, p<0.0001) than those with 207 
≥2cm of RD (1.46 years, 95% CI: 1.32 – 1.55). Each increase in performance status (reduction 208 
in ECOG PS score) saw a significantly increased median survival (Figure 2D, Table S2). PS3 was 209 
associated with a median survival of 0.67 years (95% CI: 0.43 – 1.01), while PS0 was associated 210 
with a median survival of 5.52 years (95% CI: 4.81 – 6.80) (p<0.0001, PS3 vs PS0).  Similarly, 211 
Stages I, II and III showed higher DSS compared to Stage IV (p<0.0001 for all) (Figure 2B, Table 212 
S2). 213 
 214 
Multivariable analysis of disease stage at diagnosis, histotype, time period of diagnosis, RD 215 
volume, ECOG PS and age at diagnosis reflected the univariable analyses (Table S4 and S5). 216 
Notably, these data highlight an independent association of both age and PS with DSS, despite 217 
the observed correlation between these two factors (Figure S3).  218 
 219 
Associations between clinicopathological features and outcome over time 220 
 221 
Changes in DSS and PFS over the 5-year time periods was investigated in the context of specific 222 
clinicopathological features (Table S6, Table S7). HGSOC patients demonstrated an increase in 223 
median DSS (1.56yrs, 95% CI: 1.36 – 1.92 in 1981-1985 vs 3.07yrs, 95% CI: 2.70 – 3.73 in 2011-224 
2015, p<0.0001). Stage III and IV patients showed significantly prolonged median DSS from 225 
1981-1985 to 2011-2015: 1.30yrs vs 3.44yrs (p<0.0001) and 1.03yrs vs 2.29yrs (p<0.0001) 226 
respectively. Increase in median PFS was not significant in Stage III HGSOC patients (0.98yrs 227 
vs 1.26yrs, p = 0.1049), but showed statistical significance in Stage IV HGSOC patients (0.45yrs 228 
vs 1.17yrs, p = 0.0003). ECOG PS 1 and PS 2 patients also showed significantly prolonged 229 
median DSS from 1981-1985 to 2011-2015: 1.05yrs vs 4.45yrs (p<0.0001) and 0.66yrs vs 230 
2.79yrs (p<0.0001), respectively. Patients with <2cm RD displayed apparent fluctuations in PFS 231 
over time, with recent years showing shorter median PFS (Table S7). 232 
 233 
Specifically in Stage III and IV HGSOC, median DSS improved from 1981-1985 to 2011-2015: 234 
1.36yrs vs 3.13yrs (p<0.0001) and 1.32yrs to 2.27yrs (p=0.0122) respectively (Table S8). 235 
Increase in median PFS across the same period was not significant in Stage III HGSOC (0.95yrs 236 
vs 1.25yrs, p = 0.0601) but was statistically significant in Stage IV HGSOC (0.69yrs vs 1.14yrs, 237 
p = 0.0003) (Table S9). These data mirror the results from the pan-histotype DSS and PFS 238 





Main Findings 242 
We have demonstrated and quantified the improvement in the DSS of women with epithelial 243 
OC across time at the Edinburgh Cancer Centre. A similar improvement in PFS was not seen. 244 
Differences in survival based on histotype, RD volume following debulking, ECOG PS and stage 245 
found were consistent with previous research. An increase in advanced stage HGSOC 246 
incidence and survival was seen. A strong correlation was found between increasing age at 247 
diagnosis and ECOG PS across time, indicating a shift in the clinical demographic towards an 248 
older patient population with more frequent co-morbidities.  249 
 250 
Strengths and Limitations 251 
Strengths of the study include the large number of cases and the high granularity of the 252 
prospectively collected clinical and treatment data; few similarly extensive longitudinal 253 
analyses of real-world OC data have been reported to date. Data was collected as part of 254 
routine care, almost exclusively by a single individual, optimising consistency. We recognise 255 
several limitations of this study. Firstly, criteria for defining progression have changed over 256 
time40, and were heterogeneous across the periods defined in our study. Our samples are 257 
therefore subject to varying definitions of progression over time - including CA125 and 258 
radiological evidence as well as more subjective clinical assessment. Secondly, contemporary 259 
pathology review was not carried out for all cases; lack of review for all LGSOC and high grade 260 
endometrioid cases, which have historically been poorly differentiated from HGSOCs, is a 261 
particular weakness. Moreover, the mucinous OC group had a lower rate of pathology review 262 
or contemporary diagnosis, likely a reflection of the increasing rarity of true primary mucinous 263 
OC by modern pathological criteria. However, across the whole of our OC cohort, over half of 264 
cases were confirmed by pathology review in previous studies or represented contemporary 265 
diagnoses, in contrast to previous investigations performing no such review41-43, representing 266 
a major strength of this study over previous work. Differences in practice between treating 267 
physicians and the impact of ascertainment bias also represent potential limitations.  268 
 269 
Interpretation 270 
The 5-year DSS rate observed in this study for the 2011-2015 period was 46% (95% CI: 41%-271 
51%); this is consistent with data reported by Siegel et al2. A significant improvement was seen 272 
from 1981-1985 where the 5-year survival rate was 31%. The median DSS improved 273 
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significantly from 1.73 years to 4.23 years. This improvement represents the culmination of 274 
changes in management over time, including the movement toward centralised care in 275 
centres with specialist expertise, more robust histopathological classification, improvements 276 
in disease monitoring such as imaging technology, and the introduction of additional 277 
therapeutic options. Most notably, platinum-taxane combination chemotherapy was 278 
introduced as standard of care within the study time period, and there has been a paradigm 279 
shift toward extensive cytoreductive surgery to maximise the chances of complete first-line 280 
macroscopic resection of disease25, 44, aided by neoadjuvant chemotherapy in some patients.  281 
 282 
Despite the significantly prolonged DSS observed over time, observed improvement in PFS 283 
time failed to meet statistical significance (Table S3, Figure S2). This suggests that while 284 
treatment has improved for recurrent disease, there has been little improvement in 285 
preventing or significantly prolonging relapse. This is consistent with the static standard of 286 
care for first-line OC treatment. Recent studies of first-line olaparib treatment for HGSOC 287 
BRCA1 or BRCA2 mutant patients13 and hormone maintenance for LGSOC patients45 indicate 288 
that the coming years may see an improvement in OC PFS with the routine use of these agents. 289 
Notably, however, these regimens will be limited to subsets of patients.  290 
  291 
A change in proportions of different histotypes was observed over the last 35 years with 292 
significant increases in HGSOC cases and decreases in mucinous and endometrioid cases. It is 293 
now recognised that many previously diagnosed high grade endometrioid carcinomas in fact 294 
represent variants of HGSOC46; this may explain the relative depletion of endometrioid 295 
diagnoses over time. Moreover, historic misclassification of metastatic malignancies of the 296 
gastrointestinal tract as primary mucinous OC may explain the decline in mucinous cases over 297 
time47, 48. It is therefore likely that the change in proportions of histotypes observed in this 298 
study is, at least in part, a result of a refinement in classification of tumour types.  299 
 300 
A significant increase in the proportion of HGSOC patients presenting with Stage IV disease 301 
was also observed, alongside a corresponding decrease in Stage I patients. This indicates that 302 
despite efforts to increase awareness of OC symptoms, these efforts have thus far failed to 303 
increase the proportion of early stage diagnoses. However, median DSS for these cases has 304 
increased significantly overall, and for HGSOC patients specifically (Table S9, S4), indicating 305 
post-relapse management has improved. It is also feasible that the observed increased 306 
incidence and survival in advanced stage cases is a consequence of the Will Rogers 307 
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phenomenon49, whereby advances in diagnostic techniques (such as more sensitive imaging) 308 
leads to up-staging of cases who would otherwise have been earlier stage. Certainly, increased 309 
ability of contemporary imaging to detect features such as epicardial nodes could account for 310 
a significant amount of stage shift over the time cohorts analysed. The improved outcome 311 
observed in advanced stage cases within our study is consistent with recent SEER analysis 312 
demonstrating improved outcome in this patient group50.  313 
 314 
The proportion of cases with <2cm of RD remained within the 50-60 % range for 1981-2010, 315 
showing a large increase to 88% in the 2011-2015 year range. It is likely that the emphasis on 316 
optimal debulking surgery for OC patients in recent years, driven by the recognition that 317 
complete macroscopic cytoreduction is associated with markedly favourable outcome31, has 318 
led to this increase. Moreover, this may account for decreases in median DSS and PFS seen in 319 
in the <2cm RD cohort at later diagnosis periods, as modern efforts to achieve complete 320 
macroscopic tumour resection – including radical debulking surgery and introduction of 321 
neoadjuvant chemotherapy – has enriched this cohort for poor prognosis cases over time.  322 
 323 
Difference in survival between histotypes observed in this study was generally consistent with 324 
results of previous studies46, 51, 52; LGS and endometrioid histotypes displayed better survival 325 
compared to HGSOC. Peres et al.52 found that mucinous OC displayed favourable survival at 326 
early stage, but dismal prognosis when diagnosed at advanced stage. As the majority of 327 
mucinous cases were Stage I (196/282=70%), the overall trend for favourable survival seen in 328 
this study, across time and within each 5-year cohort, is consistent with data previously 329 
reported52. Our data shows that early-stage mucinous cases show favourable outcome, while 330 
advanced-stage cases perform poorly. CC OC demonstrated poor survival at early stage and 331 
advanced stage, consistent with previous reports of intrinsic chemoresistance in CC and 332 
mucinous OC4, 53, 54, highlighting the need for targeted therapies aimed at the underlying 333 
biology of these malignancies. 334 
 335 
Previous studies have uncovered and emphasised the importance of FIGO stage55, 56 and 336 
extent of RD following debulking55, 57-59 as prognostic factors in OC. This study confirms the 337 
importance of these two factors in OC survival, as well as ECOG PS. While there have been 338 
recent reports that ECOG PS is of limited importance20, we observed a clear delineation in 339 
survival based on ECOG PS. Moreover, an adjusted multivariable model indicated an 340 




We observed a significant increase in median patient age across time (57yrs in 1981-1985 vs 343 
66yrs in 2011-2015, p<0.0001), reflective of the UK’s ageing population. A similar increase was 344 
seen on comparing the mean PS of cases across time. We show a correlation between 345 
increased ages and PS (r=0.86) across time. Multivariable analysis indicated the independent 346 
adverse associations of both of these factors on survival (Table S4, Table S5). This is indicative 347 
of the shift towards an older and frailer clinical demographic, representing a clinically 348 
challenging population characterised by co-morbidities, chemotherapy delays and poorer 349 
survival outcome60.  350 
 351 
Collectively, these data shed new light on the shifting clinical landscape of OC management, 352 
demonstrating survival improvement across time as management of OC patients has evolved. 353 
They also highlight the current areas of greatest unmet clinical need, where new therapeutic 354 
options are urgently required to improve outcome.  355 





OC survival in South-East Scotland has improved markedly over the last 35 years. Histology, 359 
stage, extent of RD and ECOG PS are strongly associated with survival outcome. Advanced 360 
stage disease has seen an increase in incidence and survival, both within HGSOC specifically 361 
and across all histotypes. Despite this, PFS has not seen a corresponding increase. Recent trials 362 
of first-line agents for specific subgroups of OC13, 45 indicate that improvement may be seen 363 
over the coming years in PFS in these groups. However, in order to see a large PFS increase in 364 
the overall OC population there is an urgent need for further improvements in first-line 365 
management. Advanced stage CC and mucinous OCs represent those patients with greatest 366 
unmet need. Moreover, the changing clinical demographic towards an older population with 367 
more co-morbidities highlights a growing patient group that represent a greater clinical 368 
challenge. 369 
Future work should aim to investigate the impact of recently introduced therapeutic options, 370 
such as anti-angiogenic therapies and PARP inhibitors, on outcome in OC. In particular, 371 
whether the use of these agents in the first-line setting leads to an improvement in the 372 
currently stagnant PFS of OC patients, should be investigated.  373 
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Table 1: Characteristics of cohort according to year of diagnosis. RD, residual disease; ECOG, Eastern Cooperative Oncology 592 
Group; FIGO, International Federation of Obstetrics and Gynaecology; NA, not available. aChi-squared test across all 593 
histotypes, 1981-1985 vs 2011-2015. bChi-squared test for stage IV vs stage I/II/III/, 1981-1985 vs 2011-2015. cChi-squared 594 
test, <2cm vs ≥2cm, 1981-1985 vs 2011-2015. dChi-squared test, PS 0 vs 1 vs 2 vs 3/4, 1981-1985 vs 2011-2015 595 
eChi-squared test across all regime classes, 1981-1985 vs 2011-2015. f35.5% of neoadjuvant cases later achieved complete 596 
macroscopic resection, vs 58.8% no macroscopic residual disease in primary debulking cases. g32.5% of neoadjuvant cases 597 
later achieved complete macroscopic resection, vs 41.7% no macroscopic residual disease in primary debulking cases. hChi-598 
squared test for neoadjuvant status, 1981-1985 vs 2011-2015 599 




Time period (year of diagnosis) N(%) P-value 
1981 - 1985 1986 - 1990 1991 - 1995 1996 - 2000 2001 - 2005 2006 - 2010 2011 - 2015  
Total Cases 223 275 374 470 471 448 544 
Histotype High grade 
serous 
129 (57.8) 153 (55.6) 203 (54.3) 295 (62.8) 315 (66.9) 285 (63.6) 373 (68.6) P<0.001a 
Clear cell 15 (6.7) 27 (9.8) 41 (11) 27 (5.7) 39 (8.3) 47 (10.5) 54 (9.9) 
Low grade 
serous 
18 (8.1) 14 (5.1) 10 (2.7) 18 (3.8) 17 (3.6) 17 (3.8) 23 (4.2) 
Mucinous 38 (17) 35 (12.7) 52 (13.9) 51 (10.9) 33 (7) 43 (9.6) 44 (8.1) 
Endometrioid 23 (10.2) 46 (16.7) 68 (18.2) 79 (16.8) 67 (14.2) 56 (12.5) 50 (9.2) 
FIGO stage at 
diagnosis 
I 49 (22) 77 (28) 83 (22.2) 97 (20.6) 72 (15.3) 87 (19.4) 92 (16.9) P=0.009b 
II 20 (9) 30 (10.9) 41 (11) 52 (11.1) 58 (12.3) 54 (12.1) 61 (11.2) 
III 119 (53.4) 131 (47.6) 188 (50.3) 231 (49.1) 246 (52.2) 188 (42) 232 (42.6) 
IV 24 (10.8) 31 (11.3) 47 (12.6) 77 (16.4) 73 (15.5) 77 (17.2) 95 (17.5) 
NA 11 (4.9) 6 (2.2) 15 (4) 13 (2.8) 22 (4.7) 42 (9.4) 64 (11.8) 
RD following 
debulk 
<2cm 116 (52) 165 (60) 199 (53.2) 236 (50.2) 229 (48.6) 213 (47.5) 342 (62.9) P<0.001c 
≥2cm 99 (44.4) 103 (37.5) 134 (35.8) 176 (37.4) 205 (43.5) 142 (31.7) 48 (8.8) 




0 73 (32.7) 112 (40.7) 83 (22.2) 102 (21.7) 79 (16.8) 52 (11.6) 98 (18) P<0.001d 
1 73 (32.7) 52 (18.9) 66 (17.6) 86 (18.3) 54 (11.5) 96 (21.4) 218 (40.1) 
2 17 (7.6) 27 (9.8) 24 (6.4) 41 (8.7) 40 (8.5) 53 (11.8) 95 (17.5) 
3 10 (4.5) 6 (2.2) 8 (2.1) 19 (4) 20 (4.2) 20 (4.5) 38 (7) 
4 0 (0) 1 (0.4) 0 (0) 0 (0) 2 (0.4) 1 (0.2) 2 (0.4) 





15 (6.7) 59 (21.5) 210 (56.1) 272 (57.9) 193 (41.0) 163 (36.4) 146 (26.8) P<0.001e 
Platinum/ 
taxane 




64 (28.7) 76 (27.6) 33 (8.8) 5 (1.1) 8 (1.7) 28 (6.3) 6 (1.1) 
Other  65 (29.1) 63 (22.9) 47 (12.6) 1 (0.2) 2 (0.4) 0 (0) 1 (0.2) 
None 79 (35.4) 77 (28) 84 (22.5) 93 (19.8) 68 (14.4) 61 (13.6) 99 (18.2) 
Neoadjuvant 
chemotherapy 
No 223 (100) 275 (100) 374 (100) 470 (100) 471 (100) 368 (82.1) 333 (61.2) P<0.001h 
Yes 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 80 (17.9)f 211 (38.8)g 
21 
 
Figure legends  601 
 602 
Figure 1: Survival rate by year of diagnosis. (a) Disease-specific survival (DSS) (b) Progression-free 603 
survival (PFS). 604 
 605 
Figure 2: Survival trends by (a) histotype DSS (b) stage DSS (c) debulk DSS (d) ECOG performance 606 
value DSS (e) advanced stage (FIGO III/IV) histotype DSS (f) advanced stage (FIGO III/IV) histotype 607 
PFS. 608 
 609 
Figure 3: (a) Boxplot of median age at diagnosis across time.   610 
(b) Scatterplot of mean ECOG performance status and mean age at diagnosis. 611 
 612 
Figure S1: Flow diagram for case inclusion. Confirmed, confirmed by contemporary pathology 613 
review; contemporary,  contemporary diagnosis (2010 onwards); historic, historic diagnosis. 614 
 615 
Figure S2: Scatterplot of median DSS and PFS increase over time. X and Y axis are in 1:1 ratio to 616 
reflect relative PFS and DSS improvement. 617 
 618 
Figure S3: Boxplot of median age at diagnosis for discrete levels of ECOG performance status. 619 
